Our Technology
Digital Diagnostics for Early Detection and Longer Health
How it Works
We combine common blood biomarkers with advanced analytics to provide diagnostic tools that are easy-to-do, noninvasive, and precise at the same time.
Our products have been trained and validated in millions of patients over 10 years to predict and stage liver health.
Used by doctors to understand their patient’s liver health, clinical organizations to screen large populations, and pharmaceutical companies to monitor patient health.
Key Features
Benefits
Fast and
Easy-to-do
Our solutions are quick and easy to carry out, as they only require 10 blood-based biomarkers to provide a result.
Noninvasive
As our tests utilize blood-based biomarkers, only a single blood draw is required to run our tests.
Accurate
Our solutions are rigorously tested and clinically validated to ensure high accuracy in detecting MASLD and MASH
Suitable for Multiple Care Settings
As our solutions can detect MASLD in early stages, and late stage MASH, our tests are suitable for both early to late stage care
High Performance & Clinical Validation
Widely used, researched, and validated.
LIVERFASt™ identifies more F4 patients than Fibroscan and FIB4
LIVERFASt™ is great for most clinical applications
LIVERFASt™ has superior performance while identifying F2 and F3 patients.
LIVERFASt™is the only NIT that identifies Fibrosis and Activity in one test.
Certified Safe & Secure
Interested in LIVERFASt™?
Contact our sales representative to inquire more about LIVERFASt™ and how it can help you and your patients improve their liver health.
Recent Publications
Combination of LIVERSTAT and Fibroscan (LSM) Outperforms FIB-4 and LSM, for MASLD Advanced Fibrosis (F3F4)
Poster presented for NASH Tag Jan 2024
LIVERFASt (L-FAST) identifies advanced (F3F4, AF) and clinically significant fibrosis (F2-F4, CSF) especially well with Fibroscan in MASLD patients (pts) from a tertiary hepatology center.
Poster presented for NASH Tag Jan 2024
The study aims to compare retrospectively the performance of one-step strategy with two noninvasive combinations, the standard-of care, FIB-4 & LSM, versus LIVERFASt-Fibrosis & LSM, for the identification of histological AF and CSF in MAFLD pts.
